David A. Cooney

Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity

David A. Cooney, Maha Dalal, Hiroaki Mitsuya et al. · Biochemical Pharmacology · 1986 · 322 citations

Medicine, Htlv-iii Infectivity, Antiviral Drug Development +8

Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine.

Carlo Federico Perno, Robert Yarchoan, David A. Cooney et al. · The Journal of Experimental Medicine · 1989 · 290 citations · Full text

Human Immunodeficiency Virus, Viral Production, Related Congeners +15

Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.

Carlo Federico Perno, Robert Yarchoan, David A. Cooney et al. · The Journal of Experimental Medicine · 1988 · 232 citations · Full text

Several Dideoxynucleosides, Human Immunodeficiency Virus, Medicine +14

The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity.

Philip S. Schein, David A. Cooney, M L Vernon · PubMed · 1967 · 190 citations

Diabetes Management, Pharmaceutical Science, Antitumor Activity +8

Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.

David A. Cooney, Neil R. Hartman, Carlo Federico Perno et al. · Molecular Pharmacology · 1988 · 160 citations